| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Physiology and Pathology and
Medicine and Neurology, University of Trieste, Trieste, Italy;
Institute of Immunology, Rikshospitalet University Hospital, Oslo, Norway;
IRCCS H. San Raffaele, Milan, Italy; and
¶ Pharmacology Section, Department of Clinical and Experimental Medicine, University of Ferrara, Ferrara, Italy
The infrequent occurrence of septic shock in patients with inherited deficiencies of the terminal complement components experiencing meningococcal disease led us to suspect that the terminal complement complex is involved in vascular leakage. To this end, the permeabilizing effect of the cytolytically inactive soluble terminal complement complex (SC5b-9) was tested in a Transwell system measuring the amount of fluorescein-labeled BSA (FITC-BSA) leaked through a monolayer of endothelial cells. The complex caused increased permeability to FITC-BSA after 15 min as opposed to the prompt response to bradykinin (BK). The effect of SC5b-9 was partially reduced by HOE-140 or CV-3988, two selective antagonists of BK B2 and platelet-activating factor receptors, respectively, and was completely neutralized by the mixture of the two antagonists. Also, DX-88, a specific inhibitor of kallikrein, partially inhibited the activity of SC5b-9. The permeabilizing factor(s) released after 30 min of incubation of endothelial cells with SC5b-9 caused a prompt leakage of albumin like BK. Intravital microscopy confirmed both the extravasation of circulating FITC-BSA across mesenteric microvessels 15 min after topical application of SC5b-9 and the complete neutralization by the mixture of HOE-140 and CV-3988. SC5b-9 induced opening of interendothelial junctions in mesenteric endothelium documented by transmission electron microscopy.
This article has been cited by other articles:
|
|
 |
|
  F. Bossi, L. Rizzi, R. Bulla, A. Debeus, C. Tripodo, P. Picotti, E. Betto, P. Macor, C. Pucillo, R. Wurzner, et al. C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function Blood, April 9, 2009; 113(15): 3640 - 3648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Corallini, F. Bossi, A. Gonelli, C. Tripodo, G. Castellino, T. E. Mollnes, F. Tedesco, L. Rizzi, F. Trotta, G. Zauli, et al. The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis Rheumatology, March 1, 2009; 48(3): 293 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Bolger, D. S. Ross, H. Jiang, M. M. Frank, A. J. Ghio, D. A. Schwartz, and J. R. Wright Complement levels and activity in the normal and LPS-injured lung Am J Physiol Lung Cell Mol Physiol, March 1, 2007; 292(3): L748 - L759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Polenghi, F. Bossi, F. Fischetti, P. Durigutto, A. Cabrelle, N. Tamassia, M. A. Cassatella, C. Montecucco, F. Tedesco, and M. de Bernard The Neutrophil-Activating Protein of Helicobacter pylori Crosses Endothelia to Promote Neutrophil Adhesion In Vivo J. Immunol., February 1, 2007; 178(3): 1312 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Macor, D. Mezzanzanica, C. Cossetti, P. Alberti, M. Figini, S. Canevari, and F. Tedesco Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res., April 1, 2006; 66(7): 3876 - 3883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Fischetti, P. Durigutto, V. Pellis, A. Debeus, P. Macor, R. Bulla, F. Bossi, F. Ziller, D. Sblattero, P. Meroni, et al. Thrombus formation induced by antibodies to {beta}2-glycoprotein I is complement dependent and requires a priming factor Blood, October 1, 2005; 106(7): 2340 - 2346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Renne, K. Schuh, and W. Muller-Esterl Local Bradykinin Formation Is Controlled by Glycosaminoglycans J. Immunol., September 1, 2005; 175(5): 3377 - 3385. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
